Huda Abdullah
About Huda Abdullah
Huda Abdullah is the Director of Global Medical Affairs - Oncology Publications at Novocure Inc. in New York, with extensive experience in oncology and medical communications.
Current Position at Novocure Inc.
Huda Abdullah serves as the Director of Global Medical Affairs for Oncology Publications at Novocure Inc., located in New York, New York. In this role, she oversees the development and dissemination of oncology publications on a global scale, contributing to the advancement of medical knowledge in the cancer treatment field.
Previous Role at Heron Therapeutics, Inc.
In 2017, Huda Abdullah worked as the Associate Director of Scientific Relations in Medical Affairs at Heron Therapeutics, Inc. for eight months. Based in Jersey City, New Jersey, she was responsible for managing scientific communications and building strong relations within the medical community.
Experience at Boehringer Ingelheim
Huda Abdullah held several key positions at Boehringer Ingelheim. She was the Associate Director of Clinical Development and Medical Affairs - Oncology in 2016 for seven months. Prior to this, she served as the Senior Manager and Manager of Clinical Development-Medical Affairs from 2012 to 2016, focusing on multiple therapeutic areas and contributing to the clinical development processes in Ingelheim, Rheinland-Pfalz, Germany.
Early Career at Ogilvy CommonHealth Worldwide
Between 2009 and 2012, Huda Abdullah was employed at Ogilvy CommonHealth Worldwide in Parsippany, New Jersey. Initially joining as a Medical Writer, she later became a Senior Medical Writer, where she played a crucial role in medical communications and publications, enhancing the agency's output in medical literature.
Educational Background
Huda Abdullah holds multiple degrees from New York Medical College, including a Doctor of Philosophy, a Doctorate between 1998 and 2007, and a Master of Science obtained from 1998 to 2001. She also has a Bachelor of Science from Pace University - Pleasantville/Briarcliff Campus, completed from 1994 to 1998.